August 2026's Asian Stocks With Estimated Value Opportunities
As of August 2026, the Asian stock markets have been navigating a complex landscape marked by global economic uncertainties and fluctuating investor sentiment. Amid this environment, identifying undervalued stocks can present unique opportunities for investors seeking to capitalize on potential value plays in the region.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| uSonar (TSE:431A) | ¥2275.00 | ¥4419.63 | 48.5% |
| SILICON2 (KOSDAQ:A257720) | ₩51800.00 | ₩103326.49 | 49.9% |
| Shiyue Daotian Group (SEHK:9676) | HK$4.625 | HK$9.20 | 49.7% |
| Shengda ResourcesLtd (SZSE:000603) | CN¥37.16 | CN¥73.24 | 49.3% |
| Sansha Electric ManufacturingLtd (TSE:6882) | ¥1191.00 | ¥2322.15 | 48.7% |
| Karmarts (SET:KAMART) | THB6.85 | THB13.36 | 48.7% |
| HyVision System (KOSDAQ:A126700) | ₩11800.00 | ₩22946.05 | 48.6% |
| HUMAN MADE (TSE:456A) | ¥1678.00 | ¥3336.53 | 49.7% |
| gremsInc (TSE:3150) | ¥2545.00 | ¥4913.63 | 48.2% |
| CMTXLtd (KOSDAQ:A388210) | ₩73200.00 | ₩144926.67 | 49.5% |
Let's review some notable picks from our screened stocks.
Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)
Overview: Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a biotechnology company focused on the research and development of novel antibody-based drugs and pre-clinical research services, with a market cap of approximately HK$53.89 billion.
Operations: Biocytogen Pharmaceuticals generates revenue through its innovative antibody-based drug development and pre-clinical research services across China, the United States, and other international markets.
Estimated Discount To Fair Value: 34%
Biocytogen Pharmaceuticals (Beijing) appears undervalued, trading over 20% below future cash flow value with a share price of HK$62 against an estimated HK$93.89. Recent guidance forecasts substantial revenue growth for the first half of 2026, with net profit up significantly due to cost efficiency and increased gross margins. The company’s strategic R&D initiatives and collaborations enhance its competitive edge, while favorable legal outcomes bolster confidence in its proprietary technology platforms.
- Our earnings growth report unveils the potential for significant increases in Biocytogen Pharmaceuticals (Beijing)'s future results.
- Click here to discover the nuances of Biocytogen Pharmaceuticals (Beijing) with our detailed financial health report.
Bona Film Group (SZSE:001330)
Overview: Bona Film Group Co., Ltd. operates in film investment, production, and distribution both in China and internationally, with a market cap of CN¥7 billion.
Operations: Bona Film Group Co., Ltd. generates revenue through its activities in film investment, production, and distribution across domestic and international markets.
Estimated Discount To Fair Value: 42.9%
Bona Film Group is trading at CNY 5.1, significantly below its estimated future cash flow value of CNY 8.93, suggesting it is undervalued by over 20%. Despite a recent net loss of CNY 168.86 million for the first half of 2026, this marks an improvement from the previous year's larger loss. Analysts forecast robust annual revenue growth of 40.7% and profitability within three years, indicating potential long-term value amidst current financial challenges.
- Upon reviewing our latest growth report, Bona Film Group's projected financial performance appears quite optimistic.
- Click to explore a detailed breakdown of our findings in Bona Film Group's balance sheet health report.
Silergy (TWSE:6415)
Overview: Silergy Corp. designs, manufactures, and sells various integrated circuit products and related technical services in China and internationally, with a market cap of NT$182.14 billion.
Operations: The company generates revenue from its semiconductors segment, amounting to NT$19.58 billion.
Estimated Discount To Fair Value: 13.9%
Silergy's current trading price of NT$469 is below its estimated future cash flow value of NT$544.66, indicating potential undervaluation. Analysts project earnings growth at a robust 41% annually, outpacing the Taiwan market average. However, the stock has shown high volatility recently and its forecasted Return on Equity remains modest at 15.7%. Despite these challenges, Silergy offers potential long-term value with significant profit growth expectations over the next three years.
- Our comprehensive growth report raises the possibility that Silergy is poised for substantial financial growth.
- Navigate through the intricacies of Silergy with our comprehensive financial health report here.
Key Takeaways
- Access the full spectrum of 219 Undervalued Asian Stocks Based On Cash Flows by clicking on this link.
- Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
- Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.
Looking For Alternative Opportunities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com